[ET Net News Agency, 3 September 2021] Daiwa lowered its target price for Sino Biopharm
(01177) to HK$11 from HK$12 and maintained its "buy" rating.
The research house said it is more optimistic on Sino Biopharm's core business recovery
but conservative on penpulimab's revenue. (RC)